Financials
| Half-year Report | Jul. 25, 2024 |
| 1st Quarter Results | Apr. 25, 2024 |
| 9M and Q3 2023 results | Nov. 09, 2023 |
| Half-year Report | Jul. 28, 2023 |
| 1st Quarter Results | Apr. 27, 2023 |
| AZ 2022 Annual Report XBRL | Feb. 21, 2023 |
| Annual Financial Report | Feb. 21, 2023 |
Proxies
| Special Business Approved at AGM | Apr. 12, 2024 |
| Proxy Form for 2024 AGM | Mar. 07, 2024 |
| Notice of AGM | Mar. 07, 2024 |
| Notice of AGM | Mar. 07, 2024 |
| Special Business Approved at AGM | Apr. 27, 2023 |
| Result of AGM | Apr. 27, 2023 |
| Notice of AGM | Mar. 22, 2023 |
Ownership Update
| Director/PDMR Shareholding | Jun. 12, 2024 |
| Director/PDMR Shareholding | May. 15, 2024 |
| Director/PDMR Shareholding | Mar. 12, 2024 |
| Director/PDMR Shareholding | Mar. 06, 2024 |
| Director/PDMR Shareholding | Mar. 06, 2024 |
| Director/PDMR Shareholding | Feb. 22, 2024 |
| Director/PDMR Shareholding | Dec. 14, 2023 |
Announcements
| ODAC reviewed Imfinzi in resectable lung cancer | Jul. 26, 2024 |
| Acquisition of Amolyt Pharma completed | Jul. 15, 2024 |
| Total Voting Rights | Jul. 01, 2024 |
| Lynparza & Imfinzi positive CHMP in endometrial | Jul. 01, 2024 |
| Update on Imfinzi ADJUVANT BR.31 trial | Jun. 25, 2024 |
| Imfinzi improved EFS and OS in bladder cancer | Jun. 25, 2024 |
| Update on CAPItello-290 Phase III trial | Jun. 18, 2024 |
Prospectuses
| AstraZeneca prices a $5bn bond offering | Feb. 22, 2024 |
| AstraZeneca prices a $2.25bn bond offering | Mar. 01, 2023 |
| AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | Jun. 15, 2022 |
| AstraZeneca prices a EUR800m bond offering | May. 27, 2021 |
| AstraZeneca prices a $7bn bond offering | May. 26, 2021 |
| AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | May. 24, 2021 |
| AstraZeneca prices a $3bn bond issue | Aug. 04, 2020 |